Literature DB >> 22939562

Galectin-3 in cardiovascular disease: a possible window into early myocardial fibrosis.

David A Morrow, Michelle L O'Donoghue.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22939562     DOI： 10.1016/j.jacc.2012.05.032

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  10 in total

Review 1.  Immunohistochemical detection of early myocardial infarction: a systematic review.

Authors:  Cristina Mondello; Luigi Cardia; Elvira Ventura-Spagnolo
Journal:  Int J Legal Med       Date:  2016-11-25       Impact factor: 2.686

Review 2.  Highlights of the year in JACC 2012.

Authors:  Anthony N DeMaria; Jeroen J Bax; Gregory K Feld; Barry H Greenberg; Jennifer L Hall; Mark A Hlatky; Wilbur Y W Lew; João A C Lima; Ehtisham Mahmud; Alan S Maisel; Sanjiv M Narayan; Steven E Nissen; David J Sahn; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2013-01-22       Impact factor: 24.094

Review 3.  Heart failure and galectin 3.

Authors:  Gabriela Suarez; Gary Meyerrose
Journal:  Ann Transl Med       Date:  2014-09

Review 4.  Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.

Authors:  Nancy J Brown
Journal:  Nat Rev Nephrol       Date:  2013-06-18       Impact factor: 28.314

5.  Galectin-3-induced oxidized low-density lipoprotein promotes the phenotypic transformation of vascular smooth muscle cells.

Authors:  Lei Tian; Kan Chen; Jiatian Cao; Zhihua Han; Lin Gao; Yue Wang; Yuqi Fan; Changqian Wang
Journal:  Mol Med Rep       Date:  2015-07-13       Impact factor: 2.952

6.  Expression of microRNA-214 and galectin-3 in peripheral blood of patients with chronic heart failure and its clinical significance.

Authors:  Ruimei Han; Ke Li; Li Li; Lili Zhang; Hongchao Zheng
Journal:  Exp Ther Med       Date:  2019-12-12       Impact factor: 2.447

7.  Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls.

Authors:  Jasper Tromp; Liselotte M Boerman; Iziah E Sama; Saskia W M C Maass; John H Maduro; Yoran M Hummel; Marjolein Y Berger; Geertruida H de Bock; Jourik A Gietema; Annette J Berendsen; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2020-02-20       Impact factor: 15.534

8.  The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study.

Authors:  Tobias Daniel Trippel; Meinhard Mende; Hans-Dirk Düngen; Djawid Hashemi; Johannes Petutschnigg; Kathleen Nolte; Christoph Herrmann-Lingen; Lutz Binder; Gerd Hasenfuss; Burkert Pieske; Rolf Wachter; Frank Edelmann
Journal:  ESC Heart Fail       Date:  2021-02-10

9.  The Diagnostic and Prognostic Value of Plasma Galectin 3 in HFrEF Related to the Etiology of Heart Failure.

Authors:  Qun Lu; Ruo-Chen Zhang; Shu-Ping Chen; Tao Li; Ya Wang; Yan-Bo Xue; Jing Liu; Xiu Han; Yi-Dan Su; Ling Bai; Xiao-Jun Du; Ai-Qun Ma
Journal:  Front Cardiovasc Med       Date:  2021-12-22

10.  Galectin-3 Interacts with Vascular Cell Adhesion Molecule-1 to Increase Cardiovascular Mortality in Hemodialysis Patients.

Authors:  Wen-Chin Ko; Cheuk-Sing Choy; Wei-Ning Lin; Shu-Wei Chang; Jian-Chiun Liou; Tao-Hsin Tung; Chih-Yu Hsieh; Jia-Feng Chang
Journal:  J Clin Med       Date:  2018-09-24       Impact factor: 4.241
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.